Evogene Valuation Multiples

Evogene is valued at $6M as of October 2026, a 4.1x revenue multiple. In the last 12 months, Evogene revenue was $2M and Evogene EBITDA was ($10M).

Evogene Overview

About Evogene

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.


Founded

1999

HQ

Israel

Employees

117

Financials (LTM)

Revenue: $2M
EBITDA: ($10M)

EV

$8M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Evogene Financials

Evogene reported last 12-month revenue of $2M and negative EBITDA of ($10M).

In the same LTM period, Evogene generated $535K in gross profit, ($10M) in EBITDA losses, and had net loss of ($11M).


Evogene P&L

In the most recent fiscal year, Evogene reported revenue of $4M and EBITDA of ($13M).

Evogene is unprofitable as of last fiscal year, with gross margin of (6%), EBITDA margin of (326%), and net margin of (220%).

See analyst estimates for Evogene
LTMLast FY2025202620272028
Revenue$2M$4M$4M
Gross Profit$535K($241K)($241K)
Gross Margin28%(6%)(6%)
EBITDA($10M)($13M)($13M)
EBITDA Margin(506%)(326%)(326%)
EBIT Margin(571%)(364%)(364%)
Net Profit($11M)($8M)($8M)
Net Margin(601%)(220%)(220%)
Net Debt-($11M)-

Financial data powered by Morningstar, Inc.

Evogene Stock Performance

Evogene has current market cap of $6M, and enterprise value of $8M.

Market Cap Evolution


Evogene's stock price is $0.38.

Evogene has an EPS (earnings per share) of $-0.54.

See more trading valuation data for Evogene
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$8M$6M-1.9%---$-0.54

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Evogene Valuation Multiples

Evogene trades at 4.1x EV/Revenue multiple, and (0.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Evogene

Evogene Financial Valuation Multiples

As of October 21, 2026, Evogene has market cap of $6M and EV of $8M.

Evogene has a P/E ratio of (0.5x).

LTMLast FY2025202620272028
EV/Revenue4.1x2.0x2.0x
EV/EBITDA(0.8x)(0.6x)(0.6x)
EV/EBIT(0.7x)(0.6x)(0.6x)
EV/Gross Profit14.5x(32.1x)(32.1x)
P/E(0.5x)(0.7x)(0.7x)
EV/FCF-(0.7x)(0.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Evogene Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Evogene Margins & Growth Rates

Evogene decreased revenue by 63% and EBITDA by 28% in the last fiscal year.

In the most recent fiscal year, Evogene reported gross margin of (6%), EBITDA margin of (326%), and net margin of (220%).

See estimated margins and future growth rates for Evogene

Evogene Margins

Last FY20252026202720282029
Gross Margin(6%)(6%)50%
EBITDA Margin(326%)(326%)(627%)
EBIT Margin(364%)(364%)(706%)
Net Margin(220%)(220%)(848%)
FCF Margin(299%)(299%)-

Evogene Growth Rates

FY+1/FY25/2626/2727/2828/29
Revenue Growth(63%)(63%)
Gross Profit Growth(400%)(400%)
EBITDA Growth(28%)(28%)
EBIT Growth(28%)(28%)
Net Profit Growth44%44%

Data powered by FactSet, Inc. and Morningstar, Inc.

Evogene Operational KPIs

Evogene's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.

Evogene's Rule of 40 is (690%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Evogene's Rule of X is (784%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Evogene
LTMLast FY2025202620272028
Rule of 40(481%)(690%)-
Bessemer Rule of X(444%)(784%)-
Revenue per Employee-$0.0M-
Opex per Employee-$0.1M-
S&M Expenses to Revenue76%5%5%
G&A Expenses to Revenue208%111%111%
R&D Expenses to Revenue311%207%207%
Opex to Revenue-358%358%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Florentaise$75M$12M0.1x-0.5x-
Dekel Agri-Vision$38M$2M1.1x0.9x20.0x10.2x
Plant Advanced Technologies$1M$777K7.2x-11.9x-
Empresa Agroindustrial Tuman------
Wilk Technologies------
Pescanova$356K$46K25.8x-199.5x-
Dhanlaxmi Seeds$4M$96K1.3x-54.5x-
Casa Emtia$23M($3M)0.2x-(1.5x)-

This data is available for Pro users. Sign up to see all Evogene competitors and their valuation data.

Start Free Trial

Investments by Evogene

Evogene has invested in 2 companies to date.

Latest investment by Evogene was on December 21st 2022. Evogene invested in Biomica in their $20M Undisclosed stage round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Evogene

Biomica
Lavie bio
Description
Biomica is an Israeli biopharmaceutical company advancing microbiome therapeutics for immune-mediated diseases, immuno-oncology, and gastrointestinal disorders. Through biomicamed.com, the platform modulates gut bacteria to enhance cancer immunotherapies and treat inflammatory bowel conditions.
Lavie Bio is a Rehovot-based Israeli agtech company engineering microbial consortia for crop enhancement and biocontrol. Products are applied via foliar sprays, seed coatings, or soil incorporation to improve yield, stress tolerance, and disease resistance in tomatoes, potatoes, and grains. Backed by Bayer and Syngenta, Lavie Bio leverages AI-driven discovery from its parent Evogene. Commercial launches include biofungicides for soil-borne pathogens, with field trials in Israel, Europe, and the U.S.
HQ CountryIsraelIsrael
HQ City
Rehovot
Rehovot
Deal Date21 Dec 20227 Aug 2019
RoundUndisclosed stageStrategic investment
Raised$20M$27M
InvestorsEvogene; Shanghai Healthcare CapitalEvogene
Valuation$100M$95M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Evogene investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Evogene

When was Evogene founded?Evogene was founded in 1999.
Where is Evogene headquartered?Evogene is headquartered in Israel.
How many employees does Evogene have?As of today, Evogene has over 117 employees.
Is Evogene publicly listed?Yes, Evogene is a public company listed on Tel Aviv Stock Exchange.
What is the stock symbol of Evogene?Evogene trades under EVGN ticker.
When did Evogene go public?Evogene went public in 2008.
Who are competitors of Evogene?Evogene main competitors include Florentaise, Dekel Agri-Vision, Plant Advanced Technologies, Empresa Agroindustrial Tuman, Wilk Technologies, Pescanova, Dhanlaxmi Seeds, Casa Emtia, Agro Pucala, Agricola Cayalti.
What is the current market cap of Evogene?Evogene's current market cap is $6M.
What is the current revenue of Evogene?Evogene's last 12 months revenue is $2M.
What is the current revenue growth of Evogene?Evogene revenue growth (NTM/LTM) is 25%.
What is the current EV/Revenue multiple of Evogene?Current revenue multiple of Evogene is 4.1x.
Is Evogene profitable?No, Evogene is not profitable.
What is the current EBITDA of Evogene?Evogene has negative EBITDA and is not profitable.
What is Evogene's EBITDA margin?Evogene's last 12 months EBITDA margin is (506%).
What is the current EV/EBITDA multiple of Evogene?Current EBITDA multiple of Evogene is (0.8x).
How many companies Evogene has acquired to date?Evogene hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Evogene has invested to date?As of October 2026, Evogene has invested in 2 companies.
What was the last Evogene investment?On 21st December 2022 Evogene invested in Biomica, participating in a $20M Undisclosed stage round at $100M valuation, alongside Shanghai Healthcare Capital.
In what companies Evogene invested in?Evogene invested in Lavie bio and Biomica.

See public comps similar to Evogene

Lists including Evogene

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial